Myxoid Leiomyosarcoma of the Uterus in a Patient Receiving Tamoxifen Therapy: A Case Report
- 1 April 2006
- journal article
- case report
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 25 (2) , 173-175
- https://doi.org/10.1097/01.pgp.0000185407.93308.ce
Abstract
In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer. The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition. A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.Keywords
This publication has 13 references indexed in Scilit:
- Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancerGynecologic Oncology, 2004
- Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcomaCancer, 2004
- Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 2004
- Association of Tamoxifen and Uterine SarcomaJournal of Clinical Oncology, 2002
- Sarcome utérin survenant au cours d’une hormonothérapie par tamoxifène. À propos de deux casLa Revue de Médecine Interne, 2001
- Risk and prognosis of endometrial cancer after tamoxifen for breast cancerThe Lancet, 2000
- Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancerRevista Do Hospital Das Clinicas, 2000
- Tamoxifen and the EndometriumInternational Journal of Gynecological Pathology, 1999
- Malignant Neoplasms of the Uterine Corpus in Patients Treated for Breast Carcinoma: The Effects of TamoxifenInternational Journal of Gynecological Pathology, 1994
- Myxoid Leiomyosarcoma of the UterusGynecologic Oncology, 1993